<부록> 고 피인용 특허

그림 16. 피인용 수에 따른 특허 수의 분포

비만치료제 기술에 속하는 특허 63455편 중 (2019-2024년 출판된 특허), 적어도 1회 이상 인용된 특허 수는 14874편(23.44%)임.
비만치료제 기술에 속하는 특허 중 피인용수가 높은 특허 리스트를 표 18 에 나타내었음.

표 18. 고 피인용 특허 목록

번호 특허제목(미국특허번호) 출원인 패밀리 특허번호 피인용 수
1 Absorbable adhesives and their formulation for use in medical applications
(10500309)
COOK BIOTECH INC(US, IN, West Lafayette) CA 2701183 A1 20090409; WO 2009045824 A2 20090409; WO 2009045824 A3 20100701; US 2009092651 A1 20090409; US 10500309 B2 20191210; GB 2465532 A 20100526; GB 201005602 D0 20100519; GB 2465532 B 20130123; AU 2008309087 A1 20090409 623
2 Tissue thickness compensator configured to redistribute compressive forces
(10624861)
Ethicon LLC(US, PR, Guaynabo) US 2022313619 A1 20221006; US 2020315983 A1 20201008; US 11559496 B2 20230124; US 2021259986 A1 20210826; US 2017367991 A1 20171228; US 10624861 B2 20200421; US 2021259987 A1 20210826; US 11850310 B2 20231226; US 2014205637 A1 20140724; US 9629814 B2 20170425 508
3 Diagnosis, removal, or mechanical damaging of tumor using plasmonic nanobubbles
(10471159)
MASIMO CORP(US, CA, Irvine) US 10471159 B1 20191112 328
4 Opioid overdose monitoring
(10932729)
MASIMO CORP(US, CA, Irvine) WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 230
5 Medicament preparation and treatment devices, methods, and systems
(10478544)
NXSTAGE MEDICAL, INC.(US, MA, Lawrence) US 11167069 B2 20211109; US 2020009308 A1 20200109; US 2022047790 A1 20220217; US 2017290970 A1 20171012; US 10478544 B2 20191119; WO 2016049542 A3 20160519; EP 3197518 A4 20180620; WO 2016049542 A2 20160331; EP 3197518 B1 20190724; EP 3197518 A2 20170802; EP 3626279 A1 20200325; EP 3560532 B1 20230419; EP 3560532 A1 20191030 215
6 Opioid overdose monitoring
(10939878)
MASIMO CORP(US, CA, Irvine) WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 210
7 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10512643)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2018092906 A1 20180405; US 10512643 B2 20191224 100
8 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10463634)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10463634 B2 20191105; US 2018256518 A1 20180913; US 2017252309 A1 20170907; US 9968568 B2 20180515 100
9 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10548857)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10548857 B2 20200204; US 2019008801 A1 20190110; US 2017304229 A1 20171026; US 10105327 B2 20181023 99
10 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
(10596167)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2016361305 A1 20161215; US 2017360776 A1 20171221; US 10092561 B2 20181009; US 10596167 B2 20200324; US 2019015407 A1 20190117 96
11 Bupropion and dextromethorphan for treating nicotine addiction
(10688066)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2019290601 A1 20190926; US 10688066 B2 20200623 95
12 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10786469)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2020093762 A1 20200326; US 10786469 B2 20200929 88
13 Combination of dextromethorphan and bupropion for treating depression
(10799497)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10799497 B2 20201013; US 2020147075 A1 20200514 88
14 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10786496)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2018360823 A1 20181220; US 10786496 B2 20200929; US 2017281617 A1 20171005; US 10105361 B2 20181023 88
15 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10780066)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10080727 B2 20180925; US 2017304230 A1 20171026; US 2019008800 A1 20190110; US 10780066 B2 20200922 88
16 Bupropion as a modulator of drug activity
(10780064)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2020261431 A1 20200820; US 2020246280 A1 20200806; US 10780064 B2 20200922 88
17 Bupropion as a modulator of drug activity
(10772850)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2020230078 A1 20200723; US 10772850 B2 20200915 88
18 Bupropion and dextromethorphan for treating nicotine addiction
(10813924)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10813924 B2 20201027; US 2020206217 A1 20200702 83
19 Bupropion as a modulator of drug activity
(10806710)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2016324807 A1 20161110; US 2017354619 A1 20171214; US 10058518 B2 20180828; US 10806710 B2 20201020; US 2019192450 A1 20190627 80
20 Opioid overdose monitoring
(11627919)
MASIMO CORP(US, CA, Irvine) WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 79
21 Bupropion as a modulator of drug activity
(10864209)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2020230131 A1 20200723; US 10864209 B2 20201215 78
22 Bupropion as a modulator of drug activity
(10894047)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10894047 B2 20210119; US 2020230130 A1 20200723 77
23 Bupropion as a modulator of drug activity
(10894046)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10894046 B2 20210119; US 2020215055 A1 20200709 77
24 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
(10881624)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2017360773 A1 20171221; US 10092560 B2 20181009; US 2016346276 A1 20161201; US 9763932 B2 20170919; US 10881624 B2 20210105; US 2019083426 A1 20190321 75
25 Bupropion as a modulator of drug activity
(10874664)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2020230129 A1 20200723; US 10874664 B2 20201229 75
26 Bupropion as a modulator of drug activity
(10874663)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2020222389 A1 20200716; US 10874663 B2 20201229 75
27 Bupropion as a modulator of drug activity
(10874665)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 10874665 B2 20201229; US 2020215058 A1 20200709 75
28 Bupropion as a modulator of drug activity
(10881657)
ANTECIP BIOVENTURES II LLC(US, NY, New York) US 2019216798 A1 20190718; US 2020222388 A9 20200716; US 10881657 B2 20210105 75
29 Biosensor performance indicator for intraoral appliances
(10639134)
ALIGN TECHNOLOGY INC(US, CA, San Jose) US 2018368961 A1 20181227; US 10639134 B2 20200505; WO 2019005808 A1 20190103; US 2023149143 A1 20230518; US 2020214817 A1 20200709; US 11576766 B2 20230214 73
30 Pharmaceutical compositions comprising meloxicam
(10471014)
AXSOME THERAPEUTICS, INC.(US, NY, New York) US 2018280306 A1 20181004; US 10471014 B2 20191112 72
31 Pharmaceutical compositions comprising meloxicam
(10471069)
AXSOME THERAPEUTICS, INC.(US, NY, New York) CA 3049229 C 20210727; CA 3049229 A1 20180712; SI 3565550 T1 20210430; BR 112019013901 A2 20200204; AU 2022200590 A1 20220317; EP 3565550 B1 20201028; KR 20230017366 A 20230203; KR 102627411 B1 20240118; EP 3565550 A4 20200122; EP 3565550 A1 20191113; CO 2019008364 A2 20190820; NZ 755129 A 20211029; KR 20190122659 A 20191030; WO 2018129220 A1 20180712; ES 2845566 T3 20210727; EP 3789016 A1 20210310; HR P20210034 T1 20210402; AU 2018205790 B2 20200709; AU 2018205790 A1 20190725; LT 3565550 T 20210325; RS 61346 B1 20210226; CA 3121746 A1 20180712; JP 2023144095 A 20231006; US 2019070192 A1 20190307; US 10265324 B2 20190423; JP 2021107413 A 20210729; PL 3565550 T3 20210719; PT 3565550 T 20210120; MX 2021014509 A 20220106; US 2018256593 A1 20180913; US 10471068 B2 20191112; US 10137131 B2 20181127; US 2018214380 A1 20180802; AU 2020244610 A1 20210121; AU 2020244610 B2 20211104; HU E052749 T2 20211228; CY 1123820 T1 20220527; KR 102493541 B1 20230130; KR 20210107157 A 20210831; KR 20240013848 A 20240130; JP 2020503360 A 20200130; DK 3565550 T3 20210118; JP 6870867 B2 20210512; CN 110621314 A 20191227; US 2019231792 A1 20190801; US 10471069 B2 20191112; MX 2019008127 A 20191202 72